PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-20.40%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
5.37%
D&A growth of 5.37% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
42.67%
Deferred tax of 42.67% while RVPH is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-15.52%
Both cut yoy SBC, with RVPH at -56.99%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
2.45%
Less working capital growth vs. RVPH's 125.07%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.66%
Negative yoy AP while RVPH is 101.70%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
389.89%
Growth well above RVPH's 159.63%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-15.52%
Negative yoy while RVPH is 81.82%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-26.74%
Negative yoy CFO while RVPH is 38.83%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
51.76%
CapEx growth of 51.76% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy purchasing while RVPH stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
169.66%
Growth of 169.66% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
253.33%
We expand invests by 253.33% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
100.00%
Debt repayment above 1.5x RVPH's 52.51%, indicating stronger deleveraging. David Dodd would verify if expansions are not neglected.
-79.28%
Negative yoy issuance while RVPH is 4129.39%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.